SAM #FDA-RFQ-13611

FDA Seeks Brightfield Group Online Data Subscription and Analytic Services for Cannabis and CBD Research

The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), is seeking a comprehensive online data subscription and analytic services package from Brightfield Group to support research and policy development related to cannabis, cannabidiol (CBD), and emerging products. - Government Buyer: - Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) - OEM/Vendor: - Brightfield Group (highlighted as the sole OEM and service provider) - Products/Services Requested: - Brightfield Group online data subscription and analytic services (1 subscription) - User support and training for unlimited FDA staff - Annual market data on CBD and emerging non-intoxicating cannabis products - Biannual consumer data updates - Daily social listening monitoring of TikTok, Instagram, and Reddit with AI modeling - Quarterly general population survey and social conversation tracking - Biannual US Cannabis Consumer Survey and social listening monitoring - Annual Women's Health Study Survey (5,000 US women) and social listening - Ad hoc work and quarterly reports on emerging concerns - Unique/Notable Requirements: - Unlimited FDA staff access to password-protected dashboards - Multiple types of surveys and social listening analytics included - Technical support and live group training sessions - Ad hoc analytic work and quarterly reporting tailored to FDA needs - Firm Fixed Price contract for a 12-month period - All services delivered online with technical support during business hours

Description

The Food and Drug Administration (FDA) requires Brightfield Group online data subscription and analytic services to help address knowledge gaps on cannabis, cannabidiol (CBD), and emerging products and help inform work on policy and regulation, education and outreach, and compliance activities.

View original listing